Noxon, a Munich-based medtech spin-off from three leading universities, has closed a multi-million-euro seed funding round to accelerate development of its non-invasive, wearable Muscle-Computer Interface. The round was led by High-Tech Gründerfonds and Bayern Kapital, with participation from Auxxo and another institutional investor.
The capital will be used to advance clinical validation and certification of the company’s platform and to prepare for the market launch of its first therapy modules.
Noxon’s technology turns muscles into digital and programmable interfaces, decoding and controlling human movement. Applications range from reducing Parkinson’s tremor and restoring motor function after paralysis to performance analysis in elite sports. As a modular platform, the company targets a market of more than 1.1 billion people affected by muscle-related conditions and aims to set new standards in rehabilitation, neurology, and wearable medtech.
In rehabilitation and neuromuscular disorders, muscle diagnostics and activation are typically conducted sporadically under clinical supervision, limiting continuous data collection and adaptive therapy in everyday life. Noxon addresses this gap by combining continuous muscle diagnostics with neuromuscular electrical stimulation in a wearable suitable for daily use. The system operates through a closed feedback loop of real-time measurement and personalized muscle and nerve activation, integrated into familiar formats such as tapes, patches, and orthopedic aids.
The company is collaborating with leading medical partners, including University Hospital Würzburg and N-Squared Lab, on pilot applications. These initiatives focus on improving muscle control when signal transmission between the brain and muscle is impaired, including solutions designed to reduce tremor in Parkinson’s patients.
Founded in 2022, Noxon focuses on non-invasive neuro- and muscle technologies, with a mission to integrate evidence-based digital care concepts into both clinical practice and everyday life.
KEY QUOTES:
“Neurological and musculoskeletal diseases are on the rise globally. Healthy muscle function is fundamental, yet often overlooked, and existing solutions tend to be too complex or costly. The support from HTGF and Bayern Kapital enables us to further validate our platform technology clinically and bring our first products to market. Our goal is to make muscle health transparent, personalized, and affordable for everyone.”
Maria Neugschwender, CEO of Noxon
“What I find so compelling about Noxon is how effective therapy can become as simple as applying a bandage. The Muscle-Computer Interface platform gives patients the opportunity to regain mobility and independence, from preventing muscle atrophy to reducing Parkinson’s tremor. That’s a true advance for quality of life.”
Dr. Lena-Sophie Schütter, Investment Manager at HTGF
“Noxon’s technology platform, which enables human muscles to be both ‘read’ and then stimulated and activated, holds significant potential across a range of applications, particularly in therapy and medical rehabilitation. Based on this approach, conditions that are currently difficult to treat, such as Parkinson’s or paralysis, could be addressed more effectively and gently for patients. This would represent major value for both medical technology and healthcare as a whole, making Noxon a very promising investment.”
Monika Steger, Managing Director of Bayern Kapital
